ROCKWELL MEDICAL,INC. (NASDAQ:RMTI) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On February11, 2019, Rockwell Medical,Inc. (the “Company”) presented at the 2019 BIO CEO& Investor Conference in New York City. A copy of the transcript from the presentation (the “Transcript”) is attached hereto as Exhibit99.1 and is incorporated herein by reference. Additionally, the Company estimates that sales for the year ended December31, 2018 will be in the range of $62 million to $63.5 million.
The information contained in this Item 2.02, including the related information set forth in the Transcript attached hereto and incorporated by reference herein, is being “furnished” and shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise. The information in this Item 2.02 shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, or into any filing or other document to the Exchange Act, except as otherwise expressly stated in any such filing. Additionally, readers are cautioned that estimated result of operations for the period ended December31, 2018 are unaudited and preliminary.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits. The following exhibit is being furnished herewith:
ROCKWELL MEDICAL, INC. Exhibit
EX-99.1 2 a19-4849_1ex99d1.htm EX-99.1 Exhibit 99.1 Transcript of Rockwell Medical,…
To view the full exhibit click
About ROCKWELL MEDICAL,INC. (NASDAQ:RMTI)
Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its lead branded drug, Triferic is indicated for iron maintenance. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Its generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. It manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.